Black Diamond Therapeutics's top three insider shareholders as of July 26, 2026 are Ali Behbahani (Director, 4.45Mn shares), Venture Capital Vi, L.P. Versant (TenPercentOwner, 3.73Mn shares), Capital Management, L.P. Ra (Director, 3.21Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Wendy L Dixon | - | 38,054 | 0 | 03 Apr, 2024 |
| Robert Alexander Ingram | - | 42,854 | 0 | 19 Dec, 2022 |
| Growth N V Biotech | - | 2,733,547 | 0 | 20 Mar, 2025 |
| Capital Management, L.P. Ra | - | 0 | 3,213,828 | 07 Jul, 2023 |
| David M. Epstein | - | 671,423 | 0 | 28 Jun, 2023 |
| Ali Behbahani | - | 0 | 4,448,757 | 06 Jul, 2023 |
| Brent Hatzis-Schoch | - | 83,400 | 0 | 31 Jan, 2025 |
| Sergey Yurasov | Chief Medical Officer | 75,000 | 0 | 31 Jan, 2025 |
| Venture Capital Vi, L.P. Versant | - | 3,726,341 | 0 | 30 Aug, 2024 |
| Mark A. Velleca | President Ceo | 121,522 | 0 | 31 Jan, 2025 |
| Elizabeth Buck | Chief Scientific Officer | 170,192 | 0 | 31 Jan, 2025 |
| Fang Ni | - | 125,389 | 0 | 23 Dec, 2022 |
| Erika Jones | - | 85,150 | 0 | 31 Jan, 2025 |
| Prakash Raman | - | 37,132 | 0 | 20 Mar, 2026 |
| Shannon Campbell | - | 8,865 | 0 | 16 Dec, 2024 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 20 Mar, 2026 | Prakash Raman | Common Stock | A | 6,105 | $2.15 | 37,132 | D | A |
| 20 Mar, 2026 | Prakash Raman | Common Stock | A | 6,105 | $2.15 | 37,132 | D | A |
| 20 Mar, 2026 | Ali Behbahani | Common Stock | A | 6,919 | $2.15 | 93,568 | D | A |
| 20 Mar, 2026 | Prakash Raman | Common Stock | A | 6,105 | $2.15 | 37,132 | D | A |
| 21 Jan, 2026 | Elizabeth Buck | Stock Option (Right to Buy) | A | 250,000 | $0.00 | 250,000 | D | A |
| 21 Jan, 2026 | Elizabeth Buck | Stock Option (Right to Buy) | A | 250,000 | $0.00 | 250,000 | D | A |
| 21 Jan, 2026 | Erika Jones | Stock Option (Right to Buy) | A | 200,000 | $0.00 | 200,000 | D | A |
| 21 Jan, 2026 | Erika Jones | Stock Option (Right to Buy) | A | 200,000 | $0.00 | 200,000 | D | A |
| 21 Jan, 2026 | Mark A. Velleca | Stock Option (Right to Buy) | A | 600,000 | $0.00 | 600,000 | D | A |
| 21 Jan, 2026 | Erika Jones | Stock Option (Right to Buy) | A | 200,000 | $0.00 | 200,000 | D | A |
| 21 Jan, 2026 | Sergey Yurasov | Stock Option (Right to Buy) | A | 250,000 | $0.00 | 250,000 | D | A |
| 21 Jan, 2026 | Mark A. Velleca | Stock Option (Right to Buy) | A | 600,000 | $0.00 | 600,000 | D | A |
| 21 Jan, 2026 | Sergey Yurasov | Stock Option (Right to Buy) | A | 250,000 | $0.00 | 250,000 | D | A |
| 21 Jan, 2026 | Elizabeth Buck | Stock Option (Right to Buy) | A | 250,000 | $0.00 | 250,000 | D | A |
| 21 Jan, 2026 | Brent Hatzis-Schoch | Stock Option (Right to Buy) | A | 250,000 | $0.00 | 250,000 | D | A |
| 21 Jan, 2026 | Sergey Yurasov | Stock Option (Right to Buy) | A | 250,000 | $0.00 | 250,000 | D | A |
| 21 Jan, 2026 | Mark A. Velleca | Stock Option (Right to Buy) | A | 600,000 | $0.00 | 600,000 | D | A |
| 12 Dec, 2025 | Prakash Raman | Common Stock | A | 4,665 | $2.76 | 31,027 | D | A |
| 12 Dec, 2025 | Prakash Raman | Common Stock | A | 4,665 | $2.76 | 31,027 | D | A |
| 12 Dec, 2025 | Ali Behbahani | Common Stock | A | 5,208 | $2.76 | 86,649 | D | A |